Skip to main content
Explore URMC

The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis

Research Question:
Does the drug, Inebilizumab, improve disability in patients with a particular type of encephalitis, call anti-N-methly-D-aspartate receptor encephalitis?

Basic Study Information

Determine the difference in disability at 16 weeks in participants with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis treated with "first-line" immunomodulatory therapies provided as standard-of-care, and either inebilizumab (investigational agent) or placebo. Inclusion Criteria 1. Diagnosis of NMDAR encephalitis 2. Age ≥ 18 years 3. Change in mental status

Location: University of Rochester
Study Reference #: STUDY00006222

Lead Researcher (Principal Investigator)

Lead Researcher:  Andrew Goodman

Study Contact Information

Study Coordinator: Christine Anne
Phone: (585) 276-3037

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search